Revision as of 10:50, 21 September 2006 editBluebot (talk | contribs)349,597 edits Unicodifying← Previous edit | Revision as of 17:57, 5 October 2006 edit undo216.153.202.18 (talk)No edit summaryNext edit → | ||
Line 20: | Line 20: | ||
{{treatment-stub}} | {{treatment-stub}}.. |
Revision as of 17:57, 5 October 2006
Noradrenergic and specific serotonergic antidepressants (abbreviated: NaSSAs) are a relatively new class of antidepressants. They are thought to act by noradrenergic autoreceptor and heteroreceptor antagonism combined with specific serotonergic antagonism. This results in increases in both noradrenergic and specific serotonergic transmission.
Examples of NaSSAs include:
- Mirtazapine (Remeron®, Zispin®, Avanza®, Norset®, Remergil®)
NaSSAs are said to have fewer side effects than tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) while being equally effective. In particular, it is said that the sexual dysfunction that is a relatively common side effect of SSRIs occurs significantly less often during treatment with NaSSAs.
See also
External links
This medical treatment–related article is a stub. You can help Misplaced Pages by expanding it. |
..
Categories: